Cantor Fitzgerald’s ADC Therapeutics ADCT Stock Holding History

Cantor Fitzgerald’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$375K	Hold	100,000	–	–	0.01%	231
2025 Q4	$353K	Buy	+100,000	New	+$406K	0.01%	189

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cantor Fitzgerald's ADCT Position: Q1 2026 in Review

Cantor Fitzgerald held its ADC Therapeutics (ADCT) position steady in Q1 2026 at 100,000 shares worth $375K. The position accounts for 0.01% of the portfolio, ranked #231.

Cantor Fitzgerald first reported a position in ADCT in Q4 2025 and has held it in 2 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

Cantor Fitzgerald held 100,000 shares of ADC Therapeutics worth $375K as of Q1 2026.
Cantor Fitzgerald left its ADC Therapeutics share count unchanged in Q1 2026.
ADC Therapeutics made up 0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #231 holding.
Cantor Fitzgerald first reported a position in ADC Therapeutics in Q4 2025 and has held it in 2 quarters since.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.